STSA insider filings
Satsuma Pharmaceuticals, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2023-06-12. Screen STSA transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for STSA between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — Satsuma Pharmaceuticals, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2023-06-12 | 4 | RA CAPITAL MANAGEMENT, L.P. RA Capital Healthcare Fund LP Kolchinsky Peter | Code (U): 5,914,252 · Disposition to issuer (D): 10,000 (derivative) @ $0 · Disposition to issuer (D): 20,000 (derivative) @ $0 · Disposition to issuer (D): 30,000 (derivative) @ $0 | EDGAR |
| 2023-06-08 | 4 | Riebe Michael T — Director | Disposition to issuer (D): 10,000 (derivative) @ $0 · Disposition to issuer (D): 20,000 (derivative) @ $0 · Disposition to issuer (D): 30,000 (derivative) @ $0 · Disposition to issuer (D): 14,893 (derivative) @ $0 · Disposition to issuer (D): 12,765 (derivative) @ $0 · Disposition to issuer (D): 12,765 (derivative) | EDGAR |
| 2023-06-08 | 4 | Harsch Mutya — Director | Disposition to issuer (D): 40,000 (derivative) @ $0 · Disposition to issuer (D): 30,000 (derivative) @ $0 | EDGAR |
| 2023-06-08 | 4 | Shin Nippon Biomedical Laboratories, Ltd. — 10% owner | Purchase (P): 22,053,581 @ $0.91 · Purchase (P): 8,423,732 @ $0.91 | EDGAR |
| 2023-06-08 | 4 | TAKANASHI KEN — Director, 10% owner | Purchase (P): 22,053,581 @ $0.91 · Disposition to issuer (D): 10,000 (derivative) @ $0 · Disposition to issuer (D): 20,000 (derivative) @ $0 · Disposition to issuer (D): 30,000 (derivative) @ $0 | EDGAR |
| 2023-06-08 | 4 | O'Neil Thomas P. — Chief Financial Officer | Code (U): 13,877 @ $0.91 · Disposition to issuer (D): 60,000 (derivative) @ $0 · Disposition to issuer (D): 80,000 (derivative) @ $0 · Disposition to issuer (D): 190,000 (derivative) @ $0 · Disposition to issuer (D): 72,340 (derivative) @ $0 · Disposition to issuer (D): 76,595 (derivative) @ $0 | EDGAR |
| 2023-06-08 | 4 | Sandoval Elisabeth — Director | Disposition to issuer (D): 10,000 (derivative) @ $0 · Disposition to issuer (D): 20,000 (derivative) @ $0 · Disposition to issuer (D): 30,000 (derivative) @ $0 · Disposition to issuer (D): 14,893 (derivative) @ $0 | EDGAR |
| 2023-06-08 | 4 | Shah Rajeev M. — Director, 10% owner | Code (U): 5,914,252 @ $0.91 · Disposition to issuer (D): 10,000 (derivative) @ $0 · Disposition to issuer (D): 20,000 (derivative) @ $0 · Disposition to issuer (D): 30,000 (derivative) @ $0 | EDGAR |
| 2023-06-08 | 4 | Lukatch Heath — Director | Disposition to issuer (D): 20,000 (derivative) @ $0 · Disposition to issuer (D): 20,000 (derivative) @ $0 · Disposition to issuer (D): 30,000 (derivative) @ $0 | EDGAR |
| 2023-06-08 | 4 | Soloway Thomas P — Director | Disposition to issuer (D): 20,000 (derivative) @ $0 · Disposition to issuer (D): 20,000 (derivative) @ $0 · Disposition to issuer (D): 30,000 (derivative) @ $0 | EDGAR |
| 2023-06-08 | 4 | Kollins John A — President and CEO, Director | Code (U): 305,911 @ $0.91 · Disposition to issuer (D): 175,000 (derivative) @ $0 · Disposition to issuer (D): 240,000 (derivative) @ $0 · Disposition to issuer (D): 505,000 (derivative) @ $0 · Disposition to issuer (D): 276,595 (derivative) @ $0 · Disposition to issuer (D): 127,659 (derivative) @ $0 · +2 more | EDGAR |
| 2023-06-08 | 4 | KING THOMAS BRAXTON — Director | Disposition to issuer (D): 10,000 (derivative) @ $0 · Disposition to issuer (D): 20,000 (derivative) @ $0 · Disposition to issuer (D): 30,000 (derivative) @ $0 · Disposition to issuer (D): 14,893 (derivative) @ $0 · Disposition to issuer (D): 12,765 (derivative) @ $0 · Disposition to issuer (D): 12,765 (derivative) | EDGAR |
| 2022-12-09 | 4/A | TAKANASHI KEN — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2022-11-23 | 4 | Leonard Braden Michael — 10% owner | Purchase (P): 150,000 @ $0.71 | EDGAR |
| 2022-11-16 | 4 | COMMODORE CAPITAL LP — 10% owner | Sale (S): 3,250,000 @ $0.71 | EDGAR |
| 2022-11-16 | 4 | Leonard Braden Michael — 10% owner | Purchase (P): 5,608,306 @ $0.69 · Purchase (P): 531,000 @ $0.63 · Purchase (P): 300,694 @ $0.63 | EDGAR |
| 2022-06-07 | 4 | Harsch Mutya — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2022-06-07 | 4 | Riebe Michael T — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2022-06-07 | 4 | TAKANASHI KEN — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2022-06-07 | 4 | O'Neil Thomas P. — Chief Financial Officer | Grant/award (A): 190,000 (derivative) @ $0 | EDGAR |
| 2022-06-07 | 4 | Sandoval Elisabeth — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2022-06-07 | 4 | Lukatch Heath — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2022-06-07 | 4 | Soloway Thomas P — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2022-06-07 | 4 | Kollins John A — President and CEO, Director | Grant/award (A): 505,000 (derivative) @ $0 | EDGAR |
| 2022-06-07 | 4 | RA CAPITAL MANAGEMENT, L.P. — Director, 10% owner RA Capital Healthcare Fund LP — Director, 10% owner Kolchinsky Peter — Director, 10% owner Shah Rajeev M. — Director, 10% owner | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2022-06-07 | 4 | ALBRECHT DETLEF — Chief Medical Officer | Grant/award (A): 190,000 (derivative) @ $0 | EDGAR |
| 2022-06-07 | 4 | KING THOMAS BRAXTON — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2021-11-29 | 4 | COMMODORE CAPITAL LP — 10% owner | Purchase (P): 2,922 @ $5.42 | EDGAR |
| 2021-11-23 | 4 | COMMODORE CAPITAL LP — 10% owner | Purchase (P): 3,225 @ $5.44 · Purchase (P): 9,979 @ $5.49 | EDGAR |
| 2021-11-12 | 4 | COMMODORE CAPITAL LP — 10% owner | Purchase (P): 9,622 @ $5.85 · Purchase (P): 7,941 @ $6.05 | EDGAR |
| 2021-11-10 | 4 | COMMODORE CAPITAL LP — 10% owner | Purchase (P): 560 @ $5.99 | EDGAR |
| 2021-11-08 | 4 | COMMODORE CAPITAL LP — 10% owner | Purchase (P): 1,400 @ $5.88 · Purchase (P): 7,800 @ $5.95 | EDGAR |
| 2021-11-04 | 4 | COMMODORE CAPITAL LP — 10% owner | Purchase (P): 8,880 @ $5.64 | EDGAR |
| 2021-11-02 | 4 | COMMODORE CAPITAL LP — 10% owner | Purchase (P): 44,651 @ $5.71 | EDGAR |
| 2021-10-29 | 4 | COMMODORE CAPITAL LP — 10% owner | Purchase (P): 39,581 @ $5.45 · Purchase (P): 15,082 @ $5.55 | EDGAR |
| 2021-10-25 | 4 | COMMODORE CAPITAL LP — 10% owner | Purchase (P): 32,816 @ $5.40 · Purchase (P): 27,629 @ $5.51 | EDGAR |
| 2021-10-21 | 4 | COMMODORE CAPITAL LP — 10% owner | Purchase (P): 87,580 @ $5.07 · Purchase (P): 40,663 @ $5.44 | EDGAR |
| 2021-10-19 | 4 | COMMODORE CAPITAL LP — 10% owner | Purchase (P): 126,000 @ $4.83 · Purchase (P): 36,194 @ $4.87 | EDGAR |
| 2021-10-12 | 4 | Harsch Mutya — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2021-04-05 | 4 | RA CAPITAL MANAGEMENT, L.P. — Director, 10% owner RA Capital Healthcare Fund LP — 10% owner Kolchinsky Peter — 10% owner Shah Rajeev M. — 10% owner | Other (J): 566,011 @ $5.91 · Other (J): 192,387 @ $5.91 | EDGAR |
| 2021-03-02 | 4 | RA CAPITAL MANAGEMENT, L.P. — Director, 10% owner RA Capital Healthcare Fund LP — Director, 10% owner Kolchinsky Peter — Director, 10% owner Shah Rajeev M. — Director, 10% owner | Purchase (P): 1,232,394 @ $5.68 | EDGAR |
| 2020-12-07 | 4 | O'Neil Thomas P. — Chief Financial Officer | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2020-12-07 | 4 | Sandoval Elisabeth — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2020-12-07 | 4 | Shah Rajeev M. — Director, 10% owner | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2020-12-07 | 4 | Lukatch Heath — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2020-12-07 | 4 | Soloway Thomas P — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2020-12-07 | 4 | Kollins John A — President and CEO, Director | Grant/award (A): 240,000 (derivative) @ $0 | EDGAR |
| 2020-12-07 | 4 | RA CAPITAL MANAGEMENT, L.P. — Director, 10% owner RA Capital Healthcare Fund LP — Director, 10% owner Kolchinsky Peter — Director, 10% owner | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2020-12-07 | 4 | ALBRECHT DETLEF — Chief Medical Officer | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2020-12-07 | 4 | KING THOMAS BRAXTON — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Satsuma Pharmaceuticals, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2023-06-08 | 8-K | 1.02 — Termination of a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-05-18 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-05-03 | 8-K | 8.01 — Other Events | EDGAR |
| 2023-04-17 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-03-28 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-02-16 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-12-20 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-11-30 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-11-14 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-11-03 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=STSA returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs